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Abstract: 
 
Background: Alzheimer’s disease is a progressive disease that degrades cognitive functioning 
and ultimately results in death. Currently, there is no cure for Alzheimer’s disease and, hence, 
the identification of preventative strategies is important. Physical activity (PA) is a behavioral 
intervention that holds promise with respect to delaying the onset of Alzheimer’s disease. 
Purpose: The purpose of this study was to explore the differential cognitive benefits achieved in 
response to PA as a function of a person’s genetic risk for AD. Methods: Older cognitively 
normal adults (50–65 years) with a family history of AD (FHxAD) participated in an 8-month 
PA program. Cognitive performance was measured at baseline, pretest, midtest, and posttest and 
changes over time were assessed as a function of apolipoprotein E (APOE) status (carriers: 1–2 
copies of the ɛ4 allele; noncarriers: 0 copies of the ɛ4 allele). Results: Improvements in memory 
were associated with PA participation irrespective of APOE ɛ4 carrier status. Conclusions: 
Future experimental studies are needed to confirm that PA causes improvements to cognitive 
performance in older cognitively normal adults with a FHxAD and that these improvements are 
equivalent for cognitively normal APOE ɛ4 carriers and noncarriers. 
 
Keywords: Exercise | APOE | Genetic risk | Executive function | Memory | Information 
processing 
 
Article: 
 
Introduction 
 
Alzheimer’s disease (AD) is a progressive neurodegenerative disease that afflicts approximately 
5.4 million Americans [1] with expectations that its prevalence will triple from 2010 to 2050. 
Currently, there is no cure for AD, thus researchers are exploring preventive strategies that could 
delay its onset [2]. One preventive strategy that is receiving attention is physical activity (PA). 
The cognitive reserve hypothesis provides a rationale for why PA might positively influence 
cognition, slow age-related cognitive decline, and delay the onset of AD [3]. This hypothesis 
suggests that cognitive reserves may be passive (related to brain structure) or active (related to 
brain function) and that reserves are decreased with advancing age or brain pathology. However, 
the hypothesis also postulates that cognitive reserves can be increased through lifestyle behaviors 
including formal education, mental stimulation through one’s occupation, and PA [4]. 
Considered together, these two propositions suggest that persons who have increased their 
cognitive reserves will have a lesser risk of dementia [4–6]. In support of the cognitive reserve 
hypothesis, there is evidence that PA benefits cognitive performance and reduces the risk of AD 
and dementia. 
 
When reviewed meta-analytically, prospective evidence shows that PA is predictive of less 
cognitive decline [7] and a reduced risk of AD and dementia [8, 9] with advancing age. There is 
also experimental evidence showing that PA results in improvements in cognitive performance 
by older cognitively normal adults [10]. One important question to consider, however, is the 
extent to which PA can be protective for individuals who have an increased risk for AD. 
Individuals who have a family history of AD (FHxAD) are at increased risk of cognitive decline 
and AD [11–13]. In addition, apolipoprotein E (APOE) is a susceptibility gene for AD [14–19]. 
There is a dose-response relationship between the APOE epsilon 4 (ɛ4) allele and the risk of AD, 
with one copy of the ɛ4 allele resulting in 3–4 times [20, 21] and 2 copies of the ɛ4 allele 
resulting in 5–18 times [22] greater risk as compared to persons without the ɛ4 allele 
(noncarriers). Hence, it is important to understand the extent to which PA is protective against 
AD in persons with a FHxAD and as a function of APOE genotype. 
 
Evidence from cross-sectional [23, 24] and prospective studies [25–32] shows that the 
relationship between PA or aerobic fitness and cognitive performance is moderated 
by APOE genotype. In particular, results from cross-sectional studies and from six of the eight 
prospective studies [25, 27–29, 31, 32] indicate that the benefits of PA for cognitive performance 
are largest for those at greatest genetic risk for AD. However, to our knowledge, there are no 
human studies that have experimentally tested APOE genotype as a moderator of the effect of 
PA on cognitive performance. Hence, the goal of this study was to conduct a PA intervention 
with older adults with a FHxAD to assess the extent to which these individuals could benefit 
from PA and to compare the cognitive benefits observed as a function of APOE ɛ4 carrier status. 
 
Methods 
 
Detailed methods and a consort flow diagram for the Physical Activity and Alzheimer’s Disease 
(PAAD) study have been previously published [33]. Hence, the study methods are briefly 
described herein. 
 
Participants 
 
Older (50–65 years) cognitively normal adults with a FHxAD were recruited in three cohorts to 
participate in an 8-month PA program. Recruitment took place via newsletters, radio 
advertisements, presentations, news columns, and flyer distribution targeted toward older adults. 
Recruitment efforts resulted in 136 individuals completing a telephone interview to initially 
determine eligibility relative to inclusion criteria and exclusion criteria. To be included in the 
study, participants had to be between 50 and 65 years of age, speak English, and fail to meet PA 
recommendations (i.e., perform fewer than 150 min of moderate intensity PA per week over the 
previous 3 months) based upon the Guidelines of the American College of Sports Medicine [34]. 
During this interview, eligibility was also determined relative to exclusion criteria for cognitive 
performance (see Cognitive Tests) and major contraindications to exercise. Of the 136 
individuals who completed the telephone interview, 20 decided not to participate after learning 
more about the required commitment and 50 were determined to be ineligible. Thus, 66 
participants completed baseline testing. Additional exclusion criteria were assessed at baseline 
testing as follows: participants were excluded from the study if they had any additional 
contraindications to PA based upon ACSM guidelines and risk categorizations (high risk were 
excluded, moderate risk were included with signed permission from their physician), had any 
chronic illness (e.g., mild-cognitive impairment, depression) or medication use (e.g., medication 
for memory problems) that would be expected to influence cognitive performance, or had 
uncorrected vision or hearing that would preclude participation in cognitive testing. After 
baseline testing, nine individuals decided they did not want to participate and three were 
excluded for health reasons. Thus, 54 participants were ultimately enrolled in the PA program. 
 
Cognitive Tests 
 
The modified Telephone Interview for Cognitive Status (TICS-m) [35] and the Folstein Mini-
Mental Status Exam (MMSE) [36] were used to screen out participants with cognitive 
impairment (mild-cognitive impairment, AD, or other forms of dementia). Participants were 
included in the study if TICS-m scores were ≥36 [35] and MMSE scores were ≥27 (including a 
score between one and three on the recall subtest) [36]. 
 
Cognitive performance relative to the PA intervention was assessed across cognitive domains 
including attention (Paced Auditory Serial Addition Test [PASAT]), memory (Rey Auditory 
Verbal Learning Test [AVLT], Rey-Osterrieth Complex Figure Test [CFT], Digit Span), 
information processing (Wechsler Adult Intelligence Scale III Digit Symbol Substitution Task 
[WAIS-DS], Trail-Making Test A [TMT A], Stroop Color Test, Stroop Word Test), and 
executive function (EF; Trail-Making Test B [TMT B], Stroop Color-Word Test, set-switching 
[TMT B – TMT A], interference [Color-Word – average of Color and Word], Tower of London 
[TOL]). These measures have well established psychometrics, were selected because they have 
been used to assess cognitive performance in cognitively normal older adults in studies focused 
on AD [37, 38], and are expected to be sensitive to the early stages of dementia [39] and/or the 
effects of PA [10]. Specific measures for each test included in the statistical analyses are shown 
in Fig. 1. 
 
PA Intervention 
 
Participants were asked to come to the University campus to participate in the PA program at 
least 3 days per week for 8 months. All exercise sessions were led by an American College of 
Sports Medicine certified exercise physiologist who was assisted by graduate students in 
Kinesiology. Each session consisted of aerobic exercise (walking around the perimeter of the 
gymnasium for 15–20 min) and strength training for 30–40 min (time increased over the course 
of the 8 months). Participants were encouraged to walk at a speed that kept their heart rate at 
60% of estimated maximal heart rate reserve (recalculated at 8-week intervals) and heart rate was 
recorded after 10 min of walking at every session. The strength training portion consisted of 
exercises completed with TheraBand resistance bands. The resistance level of the band, the 
number of exercises, the number of repetitions, and the number of sets gradually and individually 
increased over the 8-month period in response to strength gains. Exercise sessions were offered 
on 3 days of the week at three different times of day and the number of participants who were 
present at a given session ranged from 1 to 22 with six being the most common number of 
participants present at a session. Relative to prescribed sessions, the average attendance rate for 
participants who completed all of the cognitive testing sessions was 76% (see [40] for additional 
details regarding adherence). There were not significant differences in adherence as a function 
of APOE carrier status, p >.05. 
 
 
Fig. 1. Cognitive domains assessed in the study and the specific cognitive tests that were used. 
 
Genotyping 
 
Genomic DNA was extracted from buccal cell preparations at the University of North Carolina at 
Greensboro Molecular Core Laboratory for single nucleotide polymorphism (SNP) testing. The 
SNPs associated with the two amino acid residues (codons 112 and 158) were used to identify 
participants as APOE ɛ4 carriers (one or two copies of ɛ4) or APOE ɛ4 noncarriers (0 copies of 
ɛ4). Experimenters were blinded to the participants’ genotype for all exercise and testing 
sessions. 
 
 
Fig. 2. Depiction of the study procedures. 
 
Procedure 
 
See Fig. 2 for an overview of the procedures. Screening for eligibility for the study took place in 
two parts. First, interested participants were interviewed over the telephone. This interview was 
used to more fully describe the study and to assess initial inclusion (50–65 years of age, FHxAD, 
not regularly physically active) and exclusion (contraindications to exercise, TICS-m score) 
criteria. Eligible participants were invited to baseline testing during which they were asked to 
sign a consent form approved by the University’s Institutional Review Board. At this time, 
depression (using the Geriatric Depression Scale), a medical health history, the American Heart 
Association/ACSM Health/Fitness Facility Preparticipation Screening Questionnaire, and the 
MMSE were completed to further assess eligibility, and baseline cognitive measures were taken. 
Cognitive measures were obtained at baseline to allow for a dual-baseline method whereby the 
most pronounced practice effects were expected to occur between baseline and pretest allowing 
for less substantial practice effects from pretest to midtest to posttest. Those participants who 
remained eligible and interested in participating after baseline screening were then assigned in 
three cohorts to begin the 8-month PA intervention. Because participants began the PA 
intervention in cohorts, variable amounts of time passed between baseline testing and the pretest, 
but for each cohort, each test (pre-, mid-, and post-) was performed within a 2-week period. 
Cognitive testing took place in a quiet laboratory space on the University campus and was 
conducted at the pretest (prior to beginning the intervention), midtest (following the 4th month of 
the intervention), and posttest (following the 8-month intervention). In addition, at pretest, 
midtest, and posttest, distance covered during a 6-min walk was assessed to provide an estimate 
of aerobic fitness [41]. 
 
Statistical Analysis 
 
Descriptive information for the sample is presented in Table 1, and descriptive data for 
performance on the cognitive outcomes at each time point is presented in Table 2. Change in 
fitness across time was assessed using a repeated measures analysis of variance (ANOVA) with a 
Huynh-Feldt adjustment made in the case of violation of the sphericity assumption. Linear 
trajectories of change in cognitive performance across time were estimated using latent growth 
curve modeling (LGCM) [42]. Given the exploratory nature of this study, separate models were 
estimated for each cognitive outcome. This resulted in a total of 22 estimated models, grouped 
into four cognitive domains: Attention, Memory, Information Processing, and Executive 
Function. Time metrics were set at 0, 4, and 8 to model measures taken at pretest, midtest (4 
months), and posttest (8 months) relative to the PA intervention. Cognitive performance at 
baseline and APOE ɛ4 carrier status (0 = noncarrier, 1 = carrier) were entered into the models as 
predictors of intercept and slope, respectively (see Fig. 3). Baseline cognitive performance was 
included as a predictor rather than as the first outcome time point to guard against the inflation of 
the slope coefficient due to practice or maturation effects [43], and because participants did not 
take part in the intervention during the time between baseline and pretest measures. Basic 
demographic variables (i.e., age, sex, and BMI) were also included as predictors of intercept and 
slope factors in initial models. However, they were only very sparsely associated with either 
growth factor, did not substantively alter associations between baseline performance and 
intercepts or between carrier status and slopes, and their inclusion did not improve model fit. 
Therefore, these covariates were excluded from the final models. Race and education variables 
were also excluded due to homogeneity of the sample (87% White, 88.9% higher education). 
Decisions involving inclusion or exclusion of covariates were held constant across all cognitive 
outcomes (n = 22) in order to facilitate interpretation of results. Had any of the basic 
demographics been associated with either of the latent growth factors for even a moderate 
portion of outcomes, they would have been retained in all models. The only decisions that were 
made on a model-by-model basis involved instances in which it had to be determined whether 
particular model parameters should be fixed or remain freely estimated. The most common 
example was a model that yielded a small, negative, nonsignificant residual variance estimate for 
the slope factor (i.e., nonpositive definite latent variable covariance matrix). In this case, the 
residual variance for slope was fixed to zero and the model re-estimated. These restrictions were 
only imposed when doing so substantively improved reliability of the parameter estimates and 
model fit. 
 
Table 1. Descriptive data for study participants (n = 54) 
  M  SD  Range  
Age (years)  56.98  4.61  50–65  
BMI  28.13  4.12  20.3–35.6  
MMSE  29.00  3.97  27–30  
  M  SD  Range  
  n  %    
Gender  
 Female  43  79.6    
 Male  11  20.4    
Race  
 White  47  87.0    
 Black  6  11.1    
 Hispanic  0  0.0    
 Native American  0  0.0    
 Asian  0  0.0    
 Other/unknown  1  1.9    
Education  
 Up to high school  6  11.1    
 Up to Bachelor’s or Associate’s degree.  28  51.9    
 Up to Graduate degree  20  37.0    
Genotype  
 Carrier  23  43%    
 Noncarrier  31  57%    
BMI body mass index; M mean; MMSE Mini-Mental State Examination; SD standard deviation. 
 
Table 2. Means and standard deviations for cognitive outcomes organized at each time point by 
cognitive domain 
Cognitive Domain (Test)  Baseline  Pretest  Midtest  Posttest  
Attention          
 PASAT3  44.56 (11.30)  48.28 (11.26)  50.33 (9.52)  51.04 (9.38)  
 PASAT2  34.00 (9.50)  37.80 (10.76)  38.35 (10.16)  42.29 (9.61)  
Memory          
 AVLT T1  5.87 (1.85)  7.61 (2.02)  8.72 (2.20)  9.73 (2.27)  
 AVLT T6  9.94 (2.84)  11.04 (2.60)  11.54 (3.06)  12.38 (2.24)  
 AVLT delayed recall  9.41 (2.87)  11.20 (2.81)  11.63 (2.82)  12.31 (2.35)  
 AVLT recognition  13.57 (1.43)  13.91 (1.66)  14.19 (1.48)  14.42 (2.24)  
 CFT recognition  20.45 (1.79)  20.94 (1.93)  21.64 (1.46)  21.48 (1.91)  
 Recall  18.62 (6.61)  23.35 (6.64)  23.93 (5.47)  26.21 (6.87)  
 CFT delayed recall  18.36 (7.03)  22.82 (5.55)  23.69 (5.33)  25.93 (6.18)  
 DS forward  6.02 (1.22)  6.52 (1.23)  6.42 (1.51)  6.42 (1.18)  
 DS backward  4.72 (1.21)  4.80 (1.04)  4.98 (1.25)  5.20 (1.15)  
Information processing          
 CFT copy  33.94 (2.66)  34.03 (2.62)  34.10 (1.90)  34.12 (1.82)  
 WAIS-DS  51.59 (7.72)  53.67 (7.90)  54.44 (8.22)  54.53 (8.21)  
 TMT A  34.53 (7.61)  33.83 (8.21)  33.33 (10.68)  31.57 (7.12)  
 Stroop Color  65.85 (12.47)  64.45 (11.75)  65.01 (21.84)  63.79 (10.92)  
 Stroop Word  46.22 (6.85)  48.27 (10.17)  47.12 (8.91)  45.98 (7.80)  
Executive function          
 TMT B  55.24 (15.25)  56.55 (16.96)  53.45 (21.89)  52.39 (13.78)  
 TMT exec function  44.52 (15.29)  46.89 (15.41)  43.64 (21.29)  43.51 (13.05)  
 Stroop Color-Word  118.39 (27.92)  110.92 (22.55)  114.66 (29.31)  107.74 (25.26)  
 Stroop Interference  62.35 (22.71)  54.56 (16.15)  58.59 (27.38)  52.86 (23.01)  
 TOL total moves  82.08 (17.28)  74.47 (12.42)  74.23 (19.58)  73.36 (13.76)  
 TOL total time  363.89 (147.85)  312.92 (113.12)  312.45 (127.46)  302.20 (96.61)  
AVLT Auditory Verbal Learning Test; CFT Complex Figure Test; DS digit span; PASAT Paced Auditory Serial 
Addition Test; TMT Trail-Making Test; TOL Tower of London; WAIS-DS Wechsler Adult Intelligence Scale III 
Digit Symbol Substitution Task. 
 
 
Fig. 3. Model representing the linear latent growth curve analyses. 
 
There were two outcomes of primary interest in these models. One was the mean slope for each 
model, which was indicative of estimated monthly change in cognitive test performance. The 
other was the association of APOE ɛ4 carrier status with slope, which was indicative of whether 
test performance of APOE ɛ4 carriers changed at a rate different to noncarriers (i.e., moderation). 
Negative slopes and negative predictor associations were indicative of improvement for the TMT 
and the Stroop tasks, and for all measures of EF. For all other tasks, positive slopes and positive 
predictor associations with slope were indicative of improvement. Model fits were assessed by 
examining whether fit indices met commonly accepted criteria: chi-squared (p ≥ .05), root mean 
square error of approximation (<.05), comparative fit index (CFI; > .95), and Tucker Lewis 
index (TLI; > .95) and are presented in Table 3. Sample size limitations (n = 54) prevented 
estimation of higher-order (domain-level) models. Bonferroni corrections for multiple 
comparisons were determined too conservative; however, a correction factor of 10 (i.e., p < .005) 
was applied to address concerns over Type I error inflation. Further, results were interpreted in 
terms of consistency within each domain, rather than simply focusing on individual cognitive 
outcomes for which statistical significance was achieved. 
 
Table 3. Fit statistics for all latent growth models 
Attention  Χ2  df  p  RMSEA  CI90  CFI  TLI  
 PASAT3  13.33  7  0.065  0.13  0.00–0.23  0.95  0.93  
 PASAT2  13.15  7  0.069  0.13  0.00–0.23  0.96  0.95  
Attention  Χ2  df  p  RMSEA  CI90  CFI  TLI  
Memory                
 AVLT T1  4.59  5  0.469  0.00  0.00–0.18  1.00  1.00  
 AVLT T6  4.25  5  0.515  0.00  0.00–0.17  1.00  1.00  
 AVLT delayed recall  4.77  6  0.574  0.00  0.00–0.16  1.00  1.00  
 AVLT recognition  4.80  5  0.440  0.00  0.00–0.19  1.00  1.00  
 CFT delayed recognition  10.84  7  0.146  0.10  0.00–0.21  0.81  0.76  
 CFT immediate recall  14.59  7  0.042  0.14  0.03–0.25  0.94  0.93  
 CFT delayed recall  7.67  5  0.176  0.10  0.00–0.23  0.98  0.97  
 DS forward  7.13  5  0.211  0.09  0.00–0.22  0.94  0.90  
 DS backward  2.46  7  0.930  0.00  0.00–0.05  1.00  1.00  
Information processing                
 CFT copy  13.86  7  0.054  0.14  0.00–0.24  0.90  0.87  
 WAIS-DS  2.81  7  0.902  0.00  0.00–0.07  1.00  1.00  
 TMT A  5.96  7  0.544  0.00  0.00–0.15  1.00  1.00  
 Stroop Color  8.02  7  0.331  0.05  0.00–0.18  1.00  0.99  
 Stroop Word  4.92  5  0.426  0.00  0.00–0.19  1.00  1.00  
Executive function                
 TMT B  9.86  6  0.131  0.11  0.00–0.23  0.96  0.94  
 TMT set-switching  10.40  6  0.109  0.12  0.00–0.24  0.94  0.91  
 Stroop Color-Word  8.48  7  0.292  0.06  0.00–0.19  0.99  0.98  
 Stroop Interference  6.57  5  0.255  0.08  0.00–0.22  0.97  0.95  
 TOL total moves  11.91  6  0.064  0.14  0.00–0.25  0.93  0.89  
 TOL total time  11.57  6  0.072  0.13  0.00–0.25  0.95  0.92  
AVLT Auditory Verbal Learning Test; CFI comparative fit index; CFT Complex Figure Test; DS digit 
span; PASAT Paced Auditory Serial Addition Test; RMSEA root mean square error of approximation; TLI Tucker 
Lewis index; TMT Trail-Making Test; TOL Tower of London; WAIS-DS Wechsler Adult Intelligence Scale III Digit 
Symbol Substitution Task. 
 
Results 
 
Results of the repeated measures ANOVA indicated that there was a significant effect of time on 
fitness, F(1.79, 71.63) = 5.02, p = 0.01, with follow-up tests showing that fitness improved 
significantly from pretest (mean [M] = 556.79 ft, standard error [SE] = 10.26) to posttest (M = 
594.85 ft, SE = 11.22). LGCM results are presented in Table 4 and are described below. 
 
Table 4. Results from linear growth curve models for each cognitive outcome organized by 
cognitive domain 
  Intercept p Base (β) p Slope p Carrier p 
Attention 
 PASAT3  18.171 0.000 0.676 0.000 0.256 0.239 -0.026 0.912 
 PASAT2  8.994 0.012 0.836 0.000 0.384 0.017 0.068 0.772 
Memory 
 AVLT Trial 1  4.029 0.000 0.608 0.000 0.287 0.000 -0.074 0.276 
 AVLT Trial 6  5.214 0.000 0.582 0.000 0.144 0.000 0.054 0.259 
 AVLT delayed recall  6.078 0.000 0.538 0.000 0.150 0.004 -0.016 0.795 
 AVLT delayed recognition  8.731 0.000 0.376 0.017 0.093 0.031 -0.036 0.478 
 CFT delayed recognition  15.142 0.000 0.293 0.001 0.024 0.597 0.094 0.140 
 CFT immediate recall  11.275 0.000 0.635 0.000 0.335 0.001 0.012 0.930 
 CFT delayed recall  12.379 0.000 0.567 0.000 0.389 0.000 -0.045 0.703 
 DS forward  4.350 0.000 0.357 0.007 -0.002 0.930 -0.042 0.341 
 DS backward  2.753 0.000 0.431 0.000 0.044 0.087 -0.002 0.951 
Information processing 
 CFT copy  20.894 0.000 0.385 0.000 0.057 0.165 -0.037 0.615 
  Intercept p Base (β) p Slope p Carrier p 
 WAIS-DS  6.943 0.022 0.907 0.000 0.141 0.114 -0.054 0.715 
 TMT A  8.786 0.019 0.725 0.000 -0.061 0.682 -0.322 0.118 
 Stroop Color  10.524 0.009 0.819 0.000 -0.007 0.949 -0.177 0.214 
 Stroop Word  -2.172 0.662 1.088 0.000 -0.218 0.009 -0.034 0.778 
Executive function 
 TMT B  18.747 0.020 0.680 0.000 -0.302 0.293 -0.050 0.902 
 TMT set-switching  21.038 0.000 0.576 0.000 -0.280 0.335 0.007 0.987 
 Stroop Color-Word  30.075 0.001 0.684 0.000 -0.343 0.245 0.819 0.330 
 Stroop interference  21.933 0.000 0.526 0.000 -0.253 0.508 0.839 0.271 
 TOL total moves  38.297 0.001 0.441 0.003 -0.050 0.878 -0.156 0.687 
 TOL total time  137.183 0.000 0.511 0.000 -0.906 0.835 -2.156 0.401 
AVLT Auditory Verbal Learning Test; Base baseline; CFT Complex Figures Test; DS digit span; n/a indicates that 
the parameter was fixed to 0; PASAT Paced Auditory Serial Addition Test; TMT Trail-Making Test; TOL Tower of 
London. 
 
Attention 
 
Attention was assessed using two cognitive outcomes (PASAT2, PASAT3). Fit indices 
suggested poor-to-mediocre fit for both the PASAT2 and the PASAT3 models. Baseline 
performance was significantly positively predictive of the intercept for both measures of 
attention (p < .005) indicating that scores at baseline were associated with scores at pretest. 
Participants failed to demonstrate improvement across time on either the PASAT2 (p = .017) or 
the PASAT3 (p = .24) Carrier status was not significantly predictive of slope for either of the 
PASAT tasks (p’s = .77-.91). 
 
Memory 
 
Memory was assessed using nine cognitive outcomes: AVLT (Trial 1 & Trial 6, delayed recall, 
delayed recognition), CFT (immediate recall, delayed recall, delayed recognition), and Digit 
Span (Forward, Backward). Fit indices suggested good-to-excellent fit for AVLT Trial 1 and 
Trial 6, AVLT and CFT-delayed recall, AVLT delayed recognition, and Digit Span Backward 
models, poor-to-mediocre fit for the Digit Span Forward model, and poor fit for the CFT-delayed 
recognition and immediate recall models. Baseline performance was a significant positive 
predictor of intercept in all memory models (p < .001) with the exception of AVLT delayed 
recognition (p = .017), and Digit Span Forward (p = .007). Participants demonstrated significant 
improvement (i.e., significant slope factors) for AVLT Trial 1, Trial 6, delayed recall (p < .005) 
and for CFT immediate and delayed recall (p < .001). Slope factors did not reach significance for 
the AVLT delayed recognition model (p = .031), the CFT-delayed recognition model (p = .597), 
or either the Digit Span Forward (p = .930) or Backward (p = .087) models. Carrier status was 
again not significantly associated with the slope factors in any of the memory outcome models. 
 
Information Processing 
 
Information processing was assessed using five cognitive outcomes: CFT copy, WAIS-DS, TMT 
A, Stroop Color, and Stroop Word. Fit indices suggested excellent fit for all models except CFT 
copy, for which fit was poor. Baseline performance was significantly, positively predictive of 
intercept for all information processing outcomes (p < .001). Participants failed to demonstrate 
significant improvement for any of the information processing outcomes. Carrier status was 
again not significantly predictive of slope for any information processing outcomes (p = .12–
.78). 
 
Executive Function 
 
EF was assessed using six cognitive outcomes: TMT B, TMT set-switching (TMT B-TMT A), 
Stroop Color-Word time, and Stroop 
interference Stroop CW−Stroop C + Stroop W2Stroop CW−Stroop C + Stroop W2 scores, and 
TOL total moves and total time to complete. Fit indices suggested good-to-excellent fit for 
Stroop Color-Word and Stroop interference models, mediocre fit for the TMT B and TOL total 
moves models; and, poor fit for the TMT set-switching and TOL total time models. Baseline 
performance was significantly, positively predictive of intercept for all EF outcomes (p < .005). 
However, participants did not demonstrate significant change in performance (p = .24 – .99), and 
carrier status was not significantly predictive of slope for any EF outcomes (p = .27 – .99). 
 
Discussion 
 
The cognitive reserve hypothesis and evidence from past research support the expectation that 
participation in a PA program will benefit cognitive performance by older adults. There is also 
cross-sectional and prospective evidence suggesting that the effects of PA on cognitive 
performance are moderated by APOE ɛ4 carrier status. The purpose of this study was to assess 
the extent to which benefits that are associated with participation in an 8-month exercise program 
can be observed in persons with a FHxAD and to assess the extent to which these benefits differ 
as a function of one’s genetic risk for Alzheimer’s disease. 
 
Results from this study partially support past research showing that PA by older adults improves 
cognitive performance [10]. In particular, in association with their participation in an 8-month 
PA program consisting of aerobic exercise and strength training, older cognitively normal adults 
improved on multiple measures of memory. It is important to point out that study participants all 
had a FHxAD, yet the sample achieved cognitive benefits from pretest to posttest that are similar 
to what has been observed in previous samples that do not have this familial risk of AD. This is 
an important finding because of the fact that a FHxAD is associated with a heightened risk of 
AD [11, 12] and there is no known cure for AD. Further, if PA helps to maintain cognitive 
performance over time in persons with an increased risk of AD due to their familial history, this 
could have important public health implications. This is because delaying the onset of AD by as 
little as 6 months can reduce the prevalence of AD by 100,000 people after 10 years [44]. 
 
Of additional importance is the fact that these improvements were generally not influenced 
by APOE ɛ4 carrier status. That is, these results suggest that cognitively normal older adults with 
a FHxAD can achieve cognitive benefits to memory that are associated with participation in a 
PA program and that these benefits are evident irrespective of whether or not they carry 
the APOE ɛ4 allele which also heightens their genetic risk for AD. Importantly, it must be 
emphasized that because of the lack of a control group, it is not possible to know for certain if 
these improvements over time are causally related to the PA program or if they reflect practice 
effects [45]. Although we used a dual-baseline method to minimize practice effects across the 
PA intervention, past research has shown that practice effects can occur with repeated trials on 
cognitive measures like those used in this study. Hence, the lack of a control group and the 
potential for practice effects is a primary limitation of this study. 
 
As previously mentioned, the primary limitation of this study is the lack of a control group. 
However, the decision was made a priori to focus resources on a case–control study specifically 
aimed at exploring the differential effects of an 8-month PA intervention on cognitive 
performance relative to APOE ɛ4 status. While this design precludes our ability to determine 
causality, findings will facilitate the design of future randomized control trials (RCTs). 
Interpreting these results relative to previous literature is challenging because this is the first 
study in which PA was manipulated so that associated changes in cognitive performance could 
be observed. The most relevant previous literature consists exclusively of nonexperimental 
prospective studies in which researchers typically compared active individuals to inactive 
individuals by assessing changes in global cognitive performance (e.g., MMSE) or clinical 
cognitive impairment over several years. Although most of these studies suggest that the benefits 
of PA are greater for carriers of the APOE ɛ4 allele than for noncarriers, we do not believe our 
results to be inconsistent with this past literature. It is our interpretation that amongst cognitively 
normal inactive adults aged 50–65 years and with a FHxAD, both those with and without a 
heightened genetic risk for AD can achieve similar behavioral cognitive benefits from exercise. 
Subsequent research will be needed to assess the extent to which these cognitive gains slow age-
related declines in cognitive performance and lessen the risk for clinical cognitive impairment, 
both of which would be expected to be greater for the carriers than for the noncarriers [46], as 
they progress past the age range observed in the present study. 
 
One surprising finding in this study that should be acknowledged was the failure to observe 
improvements in EF in response to PA. In a meta-analytic review of RCTs with adults aged 50 
years and over, Colcombe and Kramer [10] reported the largest effects for measures of EF (g = 
0.68). Thus, we expected to see improvements in EF associated with participation in PA. 
However, Smith et al. [47]. meta-analytically reviewed RCTs with adults and reported that the 
average effect size for measures of EF was substantially smaller (g = 0.12). They suggested that 
Colcombe and Kramer’s report might have been inflated because of the inclusion of two studies 
with relatively large positive effects that were not actually RCTs. It is also possible that setting 
the upper age limit at 65 in the present study made detection of changes in EF and other 
cognitive domains more difficult. In the aforementioned meta-analysis, the reported effect sizes 
for studies with participants ranging in age from 50 to 65 years were significantly lower than 
those reported for studies with older participants [10]. This pattern is not surprising given the 
observation that the average age of onset for AD or age-related cognitive decline ranges from the 
late 60’s to 70’s depending upon APOE ɛ4 carrier status [17, 19]. 
 
In sum, this study provides initial evidence that participation in a PA program is associated with 
cognitive performance benefits to memory in older cognitively normal adults with a FHxAD and 
regardless of their APOE ɛ4 carrier status. This is consistent with past RCTs which have shown 
that PA results in improvements in cognitive performance as compared to control conditions 
[10, 47, 48], but also extends our understanding to an appreciation that these benefits can be 
obtained by persons with a FHxAD and that APOE ɛ4 carrier status does not moderate 
behavioral outcomes within this age range. Given that both persons with a FHxAD [11, 12] 
and APOE ɛ4 carriers are at a heightened risk for AD [14–19], this is important because 
increased cognitive reserves (as might be achieved through PA) may be protective against 
clinical cognitive impairment [4]. Further, prospective evidence indicates that APOE ɛ4 carriers 
who are physically active have a reduced risk of cognitive decline, dementia, and AD 
[25, 27, 28, 49]. If previously sedentary, older individuals can improve cognitive function 
through PA, the typical progression of cognitive decline may be sufficiently delayed to 
dramatically reduce an individual’s risk of AD and, at a population level, this could have an 
impact on world-wide prevalence [44]. Given that there is at this time no known cure for AD, 
further experimental research exploring the potential of PA as a preventive strategy is clearly 
warranted. 
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